Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer
A Phase Ib/II clinical trial is underway to evaluate QLC5508 and QLH12016 in combination with other therapies for advanced prostate cancer.
Asset / Drug
Drug and asset intelligence for QLC5508 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.